J. Thaddeus Beck

7.7k total citations · 3 hit papers
113 papers, 3.7k citations indexed

About

J. Thaddeus Beck is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, J. Thaddeus Beck has authored 113 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Oncology, 68 papers in Pulmonary and Respiratory Medicine and 29 papers in Molecular Biology. Recurrent topics in J. Thaddeus Beck's work include Advanced Breast Cancer Therapies (38 papers), HER2/EGFR in Cancer Research (25 papers) and Lung Cancer Treatments and Mutations (21 papers). J. Thaddeus Beck is often cited by papers focused on Advanced Breast Cancer Therapies (38 papers), HER2/EGFR in Cancer Research (25 papers) and Lung Cancer Treatments and Mutations (21 papers). J. Thaddeus Beck collaborates with scholars based in United States, Italy and France. J. Thaddeus Beck's co-authors include Matthew H. Taylor, Axel Hauschild, Sanjiv S. Agarwala, Paolo A. Ascierto, Reinhard Dummer, Carola Berking, Dirk Schadendorf, Paola Queirolo, Angela Zubel and Christian U. Blank and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

J. Thaddeus Beck

108 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

2013 499 citations J. Thaddeus Beck et al. profile →
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

2019 319 citations J. Thaddeus Beck, Kathleen N. Moore et al. profile →
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

2021 161 citations Dennis J. Slamon, Patrick Neven et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Thaddeus Beck United States	29	2.6k	1.3k	1.3k	623	525	113	3.7k
Drew Rasco United States	33	2.4k 0.9×	980 0.8×	1.7k 1.4×	516 0.8×	870 1.7×	192	4.1k
Paul Frankel United States	34	1.9k 0.7×	967 0.7×	1.8k 1.4×	658 1.1×	388 0.7×	214	4.1k
Dimitrios Bafaloukos Greece	34	3.0k 1.1×	1.6k 1.2×	1.2k 1.0×	867 1.4×	551 1.0×	132	4.5k
Valentina Boni Spain	29	2.3k 0.9×	772 0.6×	1.0k 0.8×	771 1.2×	509 1.0×	189	3.4k
Andréa Varga France	33	3.0k 1.1×	1.2k 1.0×	1.2k 1.0×	547 0.9×	816 1.6×	107	4.6k
Antoinette R. Tan United States	36	4.0k 1.5×	1.5k 1.2×	1.8k 1.4×	999 1.6×	766 1.5×	140	5.4k
Anna Berkenblit United States	26	1.4k 0.5×	1.3k 1.0×	1.6k 1.3×	710 1.1×	184 0.4×	57	3.2k
Albiruni R. Abdul Razak Canada	29	2.0k 0.8×	1.1k 0.9×	1.1k 0.9×	571 0.9×	639 1.2×	96	3.5k
Yaroslav Shparyk United States	24	3.0k 1.1×	2.4k 1.8×	870 0.7×	965 1.5×	347 0.7×	70	3.9k
José Manuel Pérez-García Spain	26	2.0k 0.7×	962 0.7×	1.5k 1.2×	891 1.4×	356 0.7×	110	3.5k

Countries citing papers authored by J. Thaddeus Beck

Since Specialization

Citations

This map shows the geographic impact of J. Thaddeus Beck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Thaddeus Beck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Thaddeus Beck more than expected).

Fields of papers citing papers by J. Thaddeus Beck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Thaddeus Beck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Thaddeus Beck. The network helps show where J. Thaddeus Beck may publish in the future.

Co-authorship network of co-authors of J. Thaddeus Beck

This figure shows the co-authorship network connecting the top 25 collaborators of J. Thaddeus Beck. A scholar is included among the top collaborators of J. Thaddeus Beck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Thaddeus Beck. J. Thaddeus Beck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hecht, J. Randolph, Alexander I. Spira, Anthony V. Nguyen, et al.. (2025). A randomized phase 2 study of an individualized neoantigen-targeting immunotherapy in patients with newly diagnosed metastatic microsatellite stable colorectal cancer (MSS-CRC).. Journal of Clinical Oncology. 43(4_suppl). 3 indexed citations

Neven, Patrick, PA Fasching, Stephen Chia, et al.. (2023). Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Research. 25(1). 103–103. 33 indexed citations

Bauer, Todd M., Kathleen N. Moore, Janet S. Rader, et al.. (2023). A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors. Targeted Oncology. 18(4). 517–530. 21 indexed citations

Yasenchak, Christopher A., Rodolfo Bordoni, Dipti Patel‐Donnelly, et al.. (2023). Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E). Blood. 142(Supplement 1). 4435–4435. 1 indexed citations

Fasching, Peter A., Guy Jérusalem, Michelino De Laurentiis, et al.. (2022). LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL). Annals of Oncology. 33. S194–S194. 7 indexed citations

Burris, Howard A., Arlene Chan, Aditya Bardia, et al.. (2021). Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. British Journal of Cancer. 125(5). 679–686. 52 indexed citations

Coleman, Robert L., J. Thaddeus Beck, Joaquina Baranda, et al.. (2021). The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials. Oncology. 99(7). 444–453. 19 indexed citations

Felip, Enriqueta, David R. Spigel, Óscar Juan, et al.. (2021). 140P Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC. Annals of Oncology. 32. S1438–S1440. 1 indexed citations

Fasching, Peter A., J. Thaddeus Beck, Arlene Chan, et al.. (2020). Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. The Breast. 54. 148–154. 27 indexed citations

10.

LoRusso, Patricia, Marwan Fakih, Filip De Vos, et al.. (2020). 561P Phase Ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic/advanced solid tumours. Annals of Oncology. 31. S484–S484. 5 indexed citations

11.

Jérusalem, Guy, Thomas E. Delea, M. Martín Jiménez, et al.. (2020). 142P Quality-adjusted survival with ribociclib plus fulvestrant (R+F) versus placebo plus fulvestrant (P+F) in postmenopausal women (PMW) HR+/HER2- advanced breast cancer (ABC) based on the MONALEESA-3 trial. Annals of Oncology. 31. S66–S66. 2 indexed citations

12.

O’Shaughnessy, Joyce, J. Thaddeus Beck, & Melanie Royce. (2018). Everolimus-based combination therapies for HR+, HER2− metastatic breast cancer. Cancer Treatment Reviews. 69. 204–214. 43 indexed citations

13.

Beeram, M., Sara M. Tolaney, J. Thaddeus Beck, et al.. (2016). A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer. Annals of Oncology. 27. vi556–vi556. 8 indexed citations

14.

Hurwitz, Herbert I., Nikhil Uppal, Stephanie A. Wagner, et al.. (2015). Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. Journal of Clinical Oncology. 33(34). 4039–4047. 237 indexed citations

15.

Voss, Martin H., Elizabeth R. Plimack, Brian I. Rini, et al.. (2015). DART Study: A phase II randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC): Results from Part 1.. Journal of Clinical Oncology. 33(7_suppl). 407–407. 2 indexed citations

16.

Saura, Cristina, Johanna C. Bendell, Guy Jérusalem, et al.. (2014). Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy. Clinical Cancer Research. 20(7). 1935–1945. 110 indexed citations

17.

Zinner, Ralph, Coleman K. Obasaju, David R. Spigel, et al.. (2014). PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 10(1). 134–142. 120 indexed citations

18.

Beck, J. Thaddeus, et al.. (2014). Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: An emerging treatment strategy for squamous cell lung carcinoma. Cancer Treatment Reviews. 40(8). 980–989. 100 indexed citations

19.

Masters, Gregory A., Athanassios Argiris, Elizabeth A. Hahn, et al.. (2006). A Randomized Phase II Trial Using Two Different Treatment Schedules of Gemcitabine and Carboplatin in Patients with Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 1(1). 19–24. 1 indexed citations

20.

Whitehead, Robert P., James Moon, Evan M. Hersh, et al.. (2004). A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy. Cancer. 100(8). 1699–1704. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact